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Abstract
Background The recent ToGA trial results indicated that
trastuzumab is a new, effective, and well-tolerated
treatment for HER2-positive gastric cancer (GC). Al-
though GC mainly affects older patients, fewer than
10% of GC patients are considered early-onset (EOGC)
(presenting at the age of 45 years or younger). These
EOGC show different clinicopathological and molecular
profiles compared to late onset GC suggesting that they
represent a separate entity within gastric carcinogenesis.
In light of potential trastuzumab benefit, subpopulations
of GC such as EOGC (versus late onset) should be
evaluated for their frequency of amplification and over-
expression using currently available techniques.
Methods Tissue microarray (TMA) blocks of 108 early
onset GC and 91 late onset GC were stained by
immunohistochemistry (IHC, Hercep test, DAKO) and
chromogenic in situ hybridization (CISH, SPoT-Light,
Invitrogen).
Results Overall, we found only 5% HER2 high level
amplification and 3% HER2 3+ overexpression (6/199).
In addition, 8 patients (4%) showed a low level CISH
amplification and 9 patients (4.5%) showed a 2+ IHC
score. IHC and CISH showed 92% concordance and
CISH showed less heterogeneity than IHC. In 2/199
cases (1%), IHC showed clinically relevant heterogeneity
between TMA cores, but all cases with focal IHC 3+
expression were uniformly CISH high level amplified.
Early onset GCs showed a significantly lower frequency
of HER2 amplification (2%) and overexpression (0%)
than late onset GCs (8% and 7% respectively) (p=0.085
and p=0.008 respectively). Proximal GC had more HER2
amplification (9% versus 3%) and overexpression (7%
versus 2%) than distal tumours although this difference
was not significant (p=0.181 and p=0.182 respectively).
HER2 CISH showed more high level amplification in the
intestinal type (7%, 16% if low-level included) compared
to the mixed (5%, 5% if low-level included) and diffuse
type (3%, 4% if low-level included) GCs (p=0.029). A
similar association was seen for HER2 IHC and histologic
type (p=0.008). Logistic regression indicated a significant
association between HER2 expression and age, which
remained significant when adjusted for both location and
histological type.
Conclusions Even focal HER2 overexpression in GC
points to uniform HER2 amplification by CISH. We show
for the first time that early onset GC has a lower frequency
of HER2 amplification and overexpression than late onset
GC, and confirm that intestinal type GC shows the highest
rate of HER2 amplification and overexpression.
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1 Introduction
Gastric cancer (GC) affects about one million people a year
and is the second leading cause of cancer-related mortality
worldwide [33]. GC exists as two main histological types,
diffuse and intestinal, as described by Laurén et al. [20],
and is thought to result from a combination of environ-
mental factors and accumulation of specific genetic alter-
ations. GC mainly affects older patients: fewer than 10% of
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gastric cancer patients are considered early-onset (EOGC)
(presenting at the age of 45 years or younger) [19]. Most
young patients present at advanced clinical stage similar to
elderly patients, so the prognosis in both age groups is poor.
It is postulated that genetic factors may play a more
important role in EOGC as in older patients as they have
less exposure to environmental carcinogens [8], thus
molecular studies in these cancers could play a key role in
the unravelling of genetic changes in gastric carcinogenesis.
Only 10% of these young patients have a positive family
history [19] which emphasises that 90% of the occurrence
of EOGC remains largely unexplained. The clinicopatho-
logical features of GC differ between young and elderly
patients. Young patients have a female preponderance, are
more often multifocal [10], more frequently develop diffuse
lesions and less frequently develop intestinal metaplasia
[19, 21, 24]. The predominance of females is considered by
some to be due to hormonal factors [22]. Furthermore,
previous studies have shown a different molecular expres-
sion profile in early-onset GC (EOGC) than in late-onset
GC [7, 27, 29]. The fact that these EOGC show different
clinicopathological and molecular profiles compared to late
onset GC suggests that they represent a separate entity
within gastric carcinogenesis.
Surgery is the mainstay of treatment for resectable
GC, but recurrence rates are high even after curative
resection. In Western countries, most patients are
diagnosed at an advanced (unresectable) stage and,
despite benefits of palliative radiotherapy and chemo-
therapy, prognosis of advanced GC remains poor
(median survival 7–10 months). Most promise to
improve this poor survival is provided by biologically
targeted agents. The ToGA study was the first random-
ized, prospective, multicenter, phase III trial to evaluate
the efficacy and safety of trastuzumab (HerceptinTM), a
humanized monoclonal anti-HER2 antibody treatment, in
HER2-positive GC [14, 16]. The modest but clinically
significant overall survival benefit indicated that trastuzu-
mab is a new, effective, and well-tolerated treatment for
HER2-positive GC. Since 1998, trastuzumab has been
used to treat more than 740,000 patients with HER2-
positive breast cancer worldwide, so there is much to learn
from the diagnostic methods developed to detect HER2
amplification and overexpression to select breast cancer
patients for this treatment. At present, the most common
methods to assess HER2 status in breast cancer are
immunohistochemistry (IHC) and chromogenic and fluo-
rescence in situ hybridization (CISH and FISH). CISH and
IHC allow easier morphologic examination than FISH,
thereby facilitating detection of heterogeneity. This is
important in GC since higher rates of heterogeneity have
been reported in GC (5%) compared to breast cancer
(1.5%)[15].
This study is of interest for treatment of gastric cancer
patients with trastuzumab. Since HER2 expression is more
often detected in intestinal type gastric cancers compared to
diffuse type gastric cancers [2, 39] and tumours of young
patients are generally known to have more frequently
diffuse type gastric cancers [32, 40], we would expect
HER2 expression to be lower in young patients. However,
some studies have suggested that HER2 positivity is
associated with poor outcome in gastric cancer, and with
more aggressive disease [12, 39, 43]. It has also been
suggested, although not consistently, that young patients
have more aggressive tumour behaviour [37, 40], in which
case we would expect HER2 expression to be higher in
young patients. Thus, the goal of this study was to assess
HER2 amplification and overexpression frequencies in a
large group (n=199) of well documented GC, including
108 EOGC and 91 late onset GC, using HER2 testing
technologies currently in use such as IHC and CISH.
2 Materials and methods
2.1 Patient material
This study involved 199 GC (of which 108 EOGC)
collected for previous studies from 24 different institutions
throughout The Netherlands, Poland, Finland and the USA.
Anonymous use of redundant tissue for research purposes is
part of the standard treatment agreement with patients in the
collaborating hospitals and all blocks were obtained
through the government approved nationwide PALGA
database with an approved scientific protocol. Tissue
microarrays were constructed from formalin-fixed paraffin
embedded archival specimens. Three core biopsies (0.6 mm
in diameter) were taken from histologically representative
regions (including heterogeneous areas) and arranged in a
new recipient paraffin block. Control samples included
normal tissue from gastric mucosa, liver and lymph node.
Four-micrometer sections were made to perform IHC and
CISH assays. From a previous study, histological grade and
stage according to the TNM 5th edition (UICC 1997) were
available [27]. Table 1 shows the clinicopathological data
of the early versus late onset patients.
2.2 Immunohistochemistry
The HercepTestTM (DAKO, Glostrup, Denmark) was used
according to the protocol of the manufacturer. Cell line
test slides provided by the manufacturer were used as
positive and negative controls. Immunostaining was
scored by one pathologist (PvD) following a 4-step scale
(0, 1+, 2+ and 3+), according to the consensus panel
recommendations on HER2 scoring for GC biopsies [15]
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with and without the additional Ruschoff criteria [34].
Scoring was done blinded to CISH results. Variation
between the IHC scores of the three cores for each case
(indicating intra-tumour heterogeneity) was noted, as well
as the clinical relevance of these variations (3+ vs. lower
scores). The highest of all three scores was used as the
final score per tumour.
2.3 Chromogenic in situ hybridization
All CISH assays were performed using the Invitrogen
SPoT-Light HER2 CISH kit according the manufacturers’
instructions. A positive control was included in each CISH
run and consisted of paraffin sections of a breast tumour
known to be HER2 amplified by CISH. For scoring, the
presence of large peroxidase-positive intra-nuclear clusters
or >10 individual small signals in >50% of tumour cells
were considered amplified. The presence of small
peroxidase-positive intra-nuclear clusters or 6–10 indi-
vidual small signals were considered low-level amplified.
Tumours with 5 or less individual small signals per
nucleus were scored as non-amplified. Scoring was done
in at least 20 tumour cells by one pathologist (PvD),
blinded to IHC results. Variations between the CISH
scores of the three cores for each case (indicating intra-
tumour heterogeneity) was noted, as well as the clinical
relevance of these variations (high-level amplified vs.
low-level amplified/normal).
2.4 Statistics
Statistics were performed using SPSS statistical software.
Contingency tables and chi-square analyses were used to
analyze associations between IHC and CISH results and
between both techniques and clinico-pathological features.
P-values below 0.05 were considered significant and post-
hoc Bonferroni correction was used to address the problem
of multiple comparisons when applicable. Binary logistic




Overall, 6/199 (3%) GC showed HER2 3+ overexpres-
sion by IHC, an additional 9/199 (4.5%) were scored 2+,
23/199 (11.5%) 1+ and the remaining 161 tumours (81%)
were negative. None of the EOGC (n=108) showed
overexpression but 7% of the other 91 late onset GC were
IHC 3+ (p=0.008). The EOGCs showed IHC 2+, 1+ and 0
scores in 2%, 6.5% and 91.5%, respectively, versus 8%,
18% and 68%, respectively, in late onset GCs.
3.2 Chromogenic in situ hybridization
CISH failed for four tumours because of overdigestion or
because less than 20 tumour cells were left for evaluation.
Overall, 9/195 (5%) GC showed HER2 high level ampli-
fication by CISH, with 8% amplification in late onset GC
and only 2% in EOGC (p=0.085). A low-level amplifica-
tion was detected in an additional 4% of the analyzed GC,
with 5% in the late onset GC group and 3% in the EOGC
group. In total, this study thereby detected 13% amplifica-
tion (low plus high level) in the late onset GC group and
5% in the EOGC group (p=0.069). Furthermore, although
many tumours were classified as non-amplified by CISH,
31% of the late onset GCs and 12% of the EOGCs had
more than 2 (but less than 6) HER2 copies.
3.3 Correlation between IHC and CISH
Table 2 and Fig. 1 show a 92% concordance between IHC
and CISH (180/195). Of the 15 discrepant tumours, 7 were
scored IHC 0/1+ while CISH was scored low-level
amplified (3/7 were EOGC), 5 were scored 2+ by IHC
but showed no CISH amplification and 3 were scored 2+
by IHC but showed amplification by CISH (2/3 were
EOGC).
Without applying Ruschoff criteria, IHC showed clini-
cally relevant heterogeneity between the three TMA cores
Table 1 Clinicopathological data of early and late onset gastric
cancer patients in this study
Early onset Late onset
n=108 n=91
HER2 0/1+ 106 76
2+ 2 8
3+ 0 7
Age Range 21–45 47–86
Median 35 68








Location Proximal 8 49
Distal 69 42
Histology Mixed 7 11
Diffuse 75 30
Intestinal 23 50
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in 4/195 (2%) cases (2x 1+/3+/CISH high level amplified,
and 2x 1+/2+/CISH high level amplified). In contrast,
CISH did not show such heterogeneity and was stable
across the three TMA cores for all cases. With Ruschoff
criteria applied, the clinically relevant heterogeneity was
reduced to 2/195 cases (2x 1+/2+/CISH high level
amplified). In total, after rescoring according to the
Ruschoff system for biopsies [34], we adjusted 21/199
scores (15x 0 to 1+ and 6x 1+ to 2+) in comparison to the
Hofmann scoring system alone [15], thereby taking into
account the three scores of all three cores per tumour (the
highest of all three scores was used as the final score per
tumour). Applying this new scoring system often resulted
in a more uniform score across the three cores. Also, in
several cases when CISH revealed more copies although
no amplification, the IHC score became 1+ (from 0) after
rescoring. However, by applying these additional criteria,
the concordance between IHC and CISH was reduced
because of the increased number of 2+ cases (9 instead of
3) without corresponding CISH amplification.
3.4 Correlations between HER2 status and clinico-
pathological features
Proximal GC had more HER2 amplification (9% versus
3%) and overexpression (7% versus 2%) than distal
tumours but this association was not significant (p=
0.181 and p=0.182 respectively). HER2 CISH showed
more high level amplification in the intestinal type (7%,
16% if low-level included) compared to the mixed (5%,
5% if low-level included) and diffuse type (3%, 4% if
low-level included) GCs (p=0.029). A similar association
was seen for HER2 IHC and histologic type (p=0.008).
There was a significant association between HER2 over-
expression and age (p=0.008) and a trend towards an
association between HER2 (low plus high level) ampli-





hybridization (CISH). a Case 1
with IHC 3+ score and
corresponding b CISH
amplification. c Case 2 with
IHC 3+ score and corresponding
d CISH amplification
HER2 CISH Total
1–5 copies 6–10 copies >10 copies
HercepTest 0/1+ 173 7 0 180
2+ 5 1 3 9
3+ 0 0 6 6
Total 178 8 9 195
Table 2 Correlation between
HercepTest immunohistochem-
istry and HER2 chromogenic in
situ hybridization (CISH) in 195
gastric carcinomas
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fication and age (p=0.069). There was no significant
correlation between HER2 amplification or overexpres-
sion levels and T- or N status.
Logistic regression indicated a significant association
between HER2 expression and age, which remained
significant when adjusted for both location and histological
type. The significant association found between HER2 and
histology type was no longer significant when age was
accounted for in the regression analysis.
4 Discussion
This study aimed to assess HER2 amplification and
overexpression frequencies in a large group (n=199) of
well documented GC, including 108 EOGC, using IHC and
CISH. Reported rates of overexpression and amplification
of HER2 in GC vary widely (2–45%) due to small sample
sizes, different study populations and methodological and
scoring differences between studies [3, 11, 15, 23, 31, 39,
44, 45]. The largest data set of >3,800 advanced GC
samples, found HER2 positivity rates of 22.1% [2, 14, 42]
and tumours classified as intestinal type were significantly
more likely to be HER2-positive (32%) than diffuse (only
6%) or mixed (20%) types. A recent review combining data
from 24 studies (6,542 patients) calculated a weighted mean
of 19% HER2 positivity [16]. The present study reports
frequencies in the lower range, with EOGC having an even
lower percentage of amplification (2%) and overexpression
(0%) than late onset GC (8% and 7% respectively). Other
studies have shown that EOGC have a different molecular
expression profile than late onset GC [26, 27] which is
consistent with the finding that these cancers show a
different (lower) HER2 overexpression and amplification
frequency than late onset GC. Other studies using whole
slides have reported lower frequencies of overexpression as
well [3, 38, 41]. A recent study used two independent
data sets and performed IHC on whole slides for one of
the data sets and on TMA slides for the other data set.
They found 9% and 4% HER2 positivity respectively,
and suggested tumour heterogeneity and subsequent
sampling error using TMA cores as the reason for this
difference in expression frequency [11]. Both series also
included young patients but it is unclear how many (only
range and median were given, both medians were >60).
Although in the present study we report low overexpres-
sion/amplification frequencies similar to Grabsch et al., we
are convinced that there is a significant difference in
HER2 expression between both age groups in our very
large set of EOGC, underlined by the results of logistic
regression analysis.
As reported in previous studies [1, 39], there was an
association between HER2 amplification/overexpression,
tumour location (proximal vs. distal) and tumour type
(intestinal vs. diffuse vs. mixed). However, after logistic
regression analysis and correction for age, these associa-
tions were no longer significant. More importantly, the
present study also reports a significant association between
HER2 overexpression and older age. It has been claimed
that young patients have a poorer prognosis [37, 40], but
others have reported that tumour staging and prognosis for
young patients is similar to older patients and depends on
whether the patients undergo a curative resection [18, 19,
24, 35]. Unfortunately this study did not include follow-up
data but no relation was found between age and lymph
node involvement or T stage (which makes prognostic
correlations unlikely), nor between HER2 status and both
prognostic factors.
A recent paper on breast cancer in young (<40 years)
patients could not find a significant correlation between
HER2 expression (2+/3+) and age, and even seemed to find
slightly more overexpression in younger patients (23%)
compared to a control group (18%) [9]. However, they did
find a higher frequency of triple negatives (ER, PR and
HER2) in the younger group. Furthermore, in breast cancer,
there does not seem to be a correlation between age of
diagnosis and reponse to trastuzumab therapy. Four large
trials of adjuvant trastuzumab demonstrated significant
improvements in disease-free survival (33%–52%) and
overall survival (34%–41%) independent from tumour size,
nodal or hormone-receptor status, and age [5]. This
indicates that gastric cancer seems to be quite different
from breast cancer in terms of HER2 expression in younger
patients, and further supports the increasing evidence that
EOGC evolves through a different molecular genetic
pathway than conventional gastric cancers [6, 7, 25–29,
36].
There are at this point some scarce reports on the
association between HER2 amplification status and re-
sponse to therapy in breast cancer. A very recent study, for
example, showed that the level of HER2 gene amplification
significantly influenced pCR but not RFS or OS in non-
metastatic breast cancer treated with trastuzumab-based
neoadjuvant therapy. However, RFS in patients with highly
amplified (HA) tumours tended to be shorter [13]. Results
from CALGB150002 have shown a relationship between
response rate to trastuzumab and HER2 copy number ratio
by FISH but also suggested that trastuzumab might be
effective in a subpopulation of breast cancer conventionally
defined as HER2 negative (because of polysomy 17), but in
fact displaying low level HER2 amplification [17]. Another
study found no significant association between HER2 copy
number and benefit and showed that even patients with
normal HER2 gene copy numbers appeared to benefit [30].
These studies thus indicate that the level of HER2
amplification plays a role in therapy response, but also that
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patients with no or lower HER2 gene copy numbers could
benefit from trastuzumab. Although detailed age informa-
tion was not published, both age groups evaluated in the
ToGA trial (<60 or ≥60 years, selected based on IHC or
FISH positivity) showed trastuzumab response but the
overall survival of the younger category seemed to be
lower (HR 0.84) than the older category (HR 0.66) in the
trastuzumab plus chemotherapy arm [2]. Furthermore, this
trial also showed that patients with diffuse type GC (more
common in EOGC) do not benefit from the addition of
trastuzumab (HR 1.07 versus HR 0.69 and HR 0.86 for
intestinal and mixed histological type, respectively). Further
studies are warranted to investigate trastuzumab sensitivity
in EOGC patients.
HER2 amplification and overexpression correlated in
92% of GC and discrepancies were mainly seen in
CISH low-level amplified and IHC 2+ cases. Concor-
dance percentages between IHC and FISH reported in
literature range between 86.9 and 96.4% [16]. This
study reports 7/180 IHC0/1+ (4%) cases to be CISH
(low-level) amplified and four of the 9 (44%) IHC 2+
cases to be CISH amplified. Our percentage of amplifi-
cation in IHC 0/1+ cases is similar to that of Bilous et al.
(5.1%) [4] but is in contrast to the results from the ToGA
trial [1] that reported a higher frequency of IHC 0/1+
samples testing FISH positive (22%) compared to that in
breast cancer.
In this TMA study, CISH showed less intratumoural
heterogeneity than IHC, even after applying the
additional scoring guideline, suggesting that CISH
would be the preferable primary screening method for
GC. Nevertheless, since this study did not use whole
slides, this should be interpreted with caution. Further-
more, the ToGA trial reported that FISH positive but
IHC 0/1+ cases did not show a substantial overall
survival benefit from trastuzumab (HR 1.07) compared
to IHC 2+/FISH positive and IHC 3+/FISH negative
cases (HR 0.65) [2], suggesting that, if this can be
independently validated, IHC should be the primary
screening method.
In conclusion, this study reports lower amplification and
overexpression frequencies than previously described but
confirms previous studies showing different frequencies
depending on the type and localisation of the GC.
Furthermore, we observed a lower amplification and over-
expression frequency in EOGC and report a slightly lower
heterogeneity rate by CISH compared to IHC.
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